title: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
abstract: BACKGROUND
  Intervention to achieve alcohol abstinence represents the most effective treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs might worsen liver disease. We aimed to investigate the effectiveness and safety of baclofen in achieving and maintaining alcohol abstinence in patients with liver cirrhosis.
  
  
  METHODS
  Between October, 2003, and November, 2006, 148 alcohol-dependent patients with liver cirrhosis were referred to the Institute of Internal Medicine, Rome, Italy. 84 were randomly allocated either oral baclofen or placebo for 12 weeks. Primary outcome was proportion of patients achieving and maintaining alcohol abstinence. Measures of this outcome were total alcohol abstinence and cumulative abstinence duration, which were assessed at outpatient visits. Relapse was defined as alcohol intake of more than four drinks per day or overall consumption of 14 or more drinks per week over a period of at least 4 weeks. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00525252.
  
  
  RESULTS
  Of 42 patients allocated baclofen, 30 (71%) achieved and maintained abstinence compared with 12 (29%) of 42 assigned placebo (odds ratio 6.3 [95% CI 2.4-16.1]; p=0.0001). The number of dropouts (termination of treatment) did not differ between the baclofen (6/42 [14%]) and placebo (13/42 [31%]) groups (p=0.12). Cumulative abstinence duration was about twofold higher in patients allocated baclofen than in those assigned placebo (mean 62.8 [SE 5.4] vs 30.8 [5.5] days; p=0.001). No hepatic side-effects were recorded.
  
  
  CONCLUSIONS
  Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis. The drug is well tolerated and could have an important role in treatment of these individuals.
authors: Institute of Internal Medicine, Catholic University of Rome, Rome, Italy. g.addolorato@rm.unicatt.it
authors: Giovanni
authors: G
authors: Addolorato
authors: Lorenzo
authors: L
authors: Leggio
authors: Anna
authors: A
authors: Ferrulli
authors: Silvia
authors: S
authors: Cardone
authors: Luisa
authors: L
authors: Vonghia
authors: Antonio
authors: A
authors: Mirijello
authors: Ludovico
authors: L
authors: Abenavoli
authors: Cristina
authors: C
authors: D'Angelo
authors: Fabio
authors: F
authors: Caputo
authors: Antonella
authors: A
authors: Zambon
authors: Paul S
authors: PS
authors: Haber
authors: Giovanni
authors: G
authors: Gasbarrini
mesh_terms: D000437:Alcoholism / Q000150:complications / Q000188:drug therapy*; D001418:Baclofen / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D018755:GABA Agonists / Q000627:therapeutic use*; D006801:Humans; D008103:Liver Cirrhosis / Q000145:classification / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D012449:Safety; D013695:Temperance
chemical_list: D018755:GABA Agonists; D001418:Baclofen